19 October-1 December 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
Channel 5
OA-05-Innovative TB diagnostics
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-05-Innovative TB diagnostics
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-05-529-21-Correlation of high-sensitivity C-reaction protein, Gene Xpert and urine LAM test for TB diagnosis in HIV-positive Kenyan patients within DREAM programme The objective of the present study is to improve tuberculosis (TB) diagnosis among HIV-positive patients using HS-CRR, LF-LAM test, 4SS and Gene Xpert. Five hundred and seventy eight Kenyan, TB-suspected patients were enrolled. Diagnosing TB infection in HIV-positive patients remains challenging, as concordance with clinical screening and different tests is suboptimal.

Fausto Ciccacci

12:43 - 12:51: OA-05-530-21-Purification of lipoarabinomannan from urine of patients with TB A multistep approach to extract urinary lipoarabinomannan (uLAM) from patients with tuberculosis (TB) and which can be scaled to use on large specimen volumes, was developed and assessed. The resulting uLAM will be used to support generation and screening of new uLAM antibodies that may increase the sensitivity of TB LAM assays.

Jason Cantera

12:51 - 12:59: OA-05-531-21-Sequence-specific hybridisation capture of urine cell-free DNA to diagnose pulmonary TB We have developed a highly-sensitive hybridisation capture assay for improved detection of TB-specific, cell-free DNA in urine. We present the results of clinical testing of our assay in urine from HIV-infected and HIV-uninfected adults with, and without, pulmonary tuberculosis in South Africa and in healthy controls in the United States. 

Amy Oreskovic

12:59 - 13:07: OA-05-532-21-Correlation between the metabolic urine profile using nuclear magnetic resonance spectrometer and the standardised case definitions for the diagnosis of childhood TB Surveillance during treatment is essential to monitor adherence and treatment response. In this proof of concept we identified a urine metabolic profiling, based on nuclear magnetic resonance of drug-sensitive pulmonary tuberculosis (TB) patients, that can identify individuals who have received treatment and changes over the course of TB treatment.

Patricia Comella-del-Barrio

13:07 - 13:15: OA-05-533-21-A novel urine method for the diagnosis of active pulmonary TB by immunoassay for the detection of ESAT-6 using hydrogel nanoparticles in HIV patients In HIV patients, tuberculosis (TB) diagnosis is difficult. A new test in urine - using hydrogel nanoparticles (NIPAm) with reactive blue - is proposed, allowing capture, preservation and concentrating ESAT-6. NIPAm are N-isopropylacrylamide copolymers, which capture and protect from enzymatic degradation. A new method for diagnosing active pulmonary TB was evaluated by immunoassay.

Raquel Mugruza

13:15 - 13:23: OA-05-534-21-Similarity algorithm for chest X-ray images: testing on large, annotated TB patient cohort and implementation of database search service We evaluated strategies for chest X-ray similarity calculation from radiomic features for application to the large, annotated image dataset in the NIAID Tuberculosis Portals (TBP). With increasingly large and well-annotated clinical image datasets, image retrieval through image similarity may help physicians identify similar patient cases with useful context for clinical care.

Conrad Shyu

13:23 - 13:31: OA-05-535-21-Diagnosis of TB through exhaled, volatile organic compounds using a real-time, high-pressure photon ionisation time-of-flight, mass spectrometry Early and accurate diagnosis and detection of tuberculosis (TB) is essential for achieving global TB control. More accurate, rapid and cost-effective screening tests are needed to improve case detection and treatment evaluation. Due to the non-invasive nature and the possibility to sample continuously, exhaled breath analysis has great clinical potential.

Liang Fu

13:31 - 13:50: Q&A


Loading...
Channel 2
SS-02-Shining a new light on TB diagnostics
event_note
Loading...
query_builder 18:15 - 19:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-02-Shining a new light on TB diagnostics
*Please scroll down for more information*
Organised by: Cepheid

The overall objective of the session will support the audience to gain deeper insights on latest innovations in TB diagnostics. 
The panelists will walk through novel technologies to improve drug-susceptibility testing, host response concepts as well as clinical insights to leverage available diagnostic tools.
* CE-IVD. In Vitro Diagnostic Medical Device. Product not available in the United States.

18:15 - 18:25: Introduction


18:25 - 18:45: Behind the scenes – Innovations in TB diagnostics Dr. Gnanashanmugam will share insights about the innovation behind the Xpert® MTB/XDR assay* and Cepheid’s technology.

Devasena Gnanashanmugam

18:45 - 19:05: Evaluation of Xpert® MTB/XDR* and possibilities of integration into the National diagnostic algorithm – the South African perspective Dr. Omar will present the first clinical evaluation of the recently launched Xpert® MTB/XDR* assay in South Africa.
* CE-IVD. In Vitro Diagnostic Medical Device. Product not available in the United States.

Shaheed Vally Omar

19:05 - 19:25: Demonstrating the power of heterogeneity: from discovery to point-of-care using public data for tuberculosis diagnosis Dr. Khatri will speak about host response gene signatures in Tuberculosis and share further insights.

Purvesh Khatri

19:25 - 19:45: Using available TB diagnostics to Guide Patient Management – A Clinical Perspective Prof. Kon will share his experience as a clinical expert in how to leverage diagnostic tools for patient management.  
 

Onn Min Kon

Loading...
Channel 2
SP-22-Advancing a prevention research agenda for TB
event_note
Loading...
query_builder 16:30 - 17:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-22-Advancing a prevention research agenda for TB
*Please scroll down for more information*
Prevention is essential to achieving global targets to end the tuberculosis (TB) epidemic and should be considered an essential human right. In recent years there has been increased focus on advancing research and development of new tools to support TB prevention, including diagnostics to detect latent TB infection, therapeutics to prevent progression to active disease and vaccines to prevent Mycobacterium tuberculosis infection or to prevent progression to disease. This session will provide an overview of the status of development of new vaccines, drugs and diagnostics to diagnose and prevent TB disease. A human rights framework for TB prevention will also be presented.

16:30 - 16:35: Introduction

16:35 - 16:47: Prevention through vaccination: advancing research and development of new vaccines to prevent TBVaccines are one of the most successful and effective public health interventions to decrease the spread of life-threatening infectious diseases. Worldwide, incidence and death due to measles, diptheria, influenza, polio, meningitis and numerous other diseases have been greatly reduced through effective vaccines and immunisation programmes. However, BCG, the only licensed vaccine to prevent tuberculosis (TB), has been inadequate in halting the global epidemic. Over the past two decades there has been a significant global effort to develop new, more effective TB vaccines and recent promising results have demonstrated that developing new vaccines is feasible, bringing increased enthusiasm and optimism to the field. This presentation will discuss the latest advances in the research and development of new, more effective vaccines to prevent TB, the potential impact a new TB vaccine could have on TB incidence, and what will be necessary to further advance the TB vaccine pipeline.
Grace Kaguthi

16:47 - 16:59: Diagnosing TB infection to prevent TB: an overview of the landscape of TB infection and incipient TB testsExisting tests for TB infection (TBI), tuberculin skin test (TST) and Interferon Gamma Release Assays (IGRA), have limited value in predicting risk for the progression from infection to active TB. Furthermore, implementation of TBI tests faces operational challenges such as cold chain requirements and needs for sophisticated laboratory infrastructure. Partly as a result of logistic challenges and limitations in their accuracy, TBI tests are not required prior to the start of TB preventive treatment (TPT) in priority risk groups such as people living with HIV and household contacts aged less than 5 years. For others, TBI tests are generally recommended to identify those who benefit most from treatment.  New tests for TBI are emerging such as the C-Tb (Serum Institute of India), Diaskin Test (Generium, Russian Federation) and QFT access (Qiagen, SA). It is important to review the landscape of TBI tests and identify gaps that need to be filled to facilitate development and introduction of new tests.
Morten Ruhwald

16:59 - 17:11: TB preventive therapy: treatment of latent TB infection with a shorter course regimenRoughly one quarter of the world is infected with latent tuberculosis infection (LTBI) and treating this population is critical to achieving the end of the TB epidemic. While treatment of active TB has remained a top priority, this strategy alone will not yield the needed results to meet these END TB targets. Current treatments for LTBI can take up to nine months and adherence to such lengthy treatments have proved inconsistent in the past. Newer, shorter-course preventative therapies are needed if we are to achieve the reductions in TB cases needed to meet the END TB targets.
Richard Chaisson

17:11 - 17:23: What's law got to do with it? New technologies for TB prevention and emerging human rights issuesThe role of law and human rights in the global tuberculosis (TB) response have been increasingly recognised as central to achieving global targets set in the End TB strategy and the United Nations Political Declaration on TB. Despite this, there is a lack of understanding and implementation of a human rights-based disease response. As new vaccine, diagnostic and treatment technologies emerge, including to prevent TB infection and/or disease and to diagnose and treat latent TB infection, the law and rights will play an even greater role in either supporting or hindering efforts to end the epidemic. Building on the other talks in this session, this presentation will consider the opportunities and risks associated with legal frameworks and human rights law to promote the availability and accessibility of new TB preventive technologies. The talk will focus on intellectual property and trade law and the rights to health and science.
Brian Citro

17:23 - 17:50: Q&A session

Loading...
Channel 4
SS-07-Advancements in the TB diagnostics pipeline: FIND and NDWG annual  symposium
event_note
Loading...
query_builder 18:15 - 19:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-07-Advancements in the TB diagnostics pipeline: FIND and NDWG annual  symposium
*Please scroll down for more information*
Organised by: FIND and NDWG
Tuberculosis (TB) diagnostics are needed to detect exposure, diagnose disease and drug resistance, and to monitor improvement under treatment in both primary healthcare and laboratory settings. The Foundation for Innovative New Diagnostics (FIND) and the Stop TB  Partnership’s New Diagnostics Working Group (NDWG) bring to you the latest developments in TB diagnostics R&D. You will hear from leading  global experts on the advancements in the TB diagnostics pipeline, improvements in the detection of drug-resistant TB, next-generation  sequencing and the diagnosis of TB infection.

18:15 - 18:20: Introduction

Daniela Cirillo

18:20 - 18:40: TB diagnostics pipeline update: 2020 and beyond While we can accelerate progress, we cannot end the tuberculosis (TB) epidemic with the tools that we have today. We need rapid, and  affordable, non-sputum based tests for diagnosis or triage, accurate drug-susceptibility testing for critical medicines, and better tools to detect TB infection and testing for risk of progression to active disease. We are working with our partners and donors to make easy-to-use, robust, reliable and highly accurate tests a reality in routine clinical settings, particularly at the lower levels of care. Our R&D efforts are  focused on areas of critical unmet needs. Our session brings to you the most comprehensive update on the TB diagnostics pipeline in 2020  and beyond.

Morten Ruhwald

18:40 - 18:50: Recent advances in the diagnosis of drug-resistant TB The development and implementation of rapid molecular diagnostics for tuberculosis (TB) drug-susceptibility testing (DST) is critical to inform patient treatment and to prevent the emergence and spread of resistance. We report results from two recently completed  multicentre diagnostic accuracy studies: 1. the Xpert MTB/XDR assay (Cepheid, USA) for detecting resistance to isoniazid (INH), ethionamide (ETH), fluoroquinolones (FQs) and secondline injectables,amikacin (AMK), kanamycin (KAN), and capreomycin (CAP), and 2) the Molbio Truenat molecular diagnostic assays for detection of M.tb and RIF-resistance.

Adam Penn-Nicholson

18:50 - 19:00: Seq&Treat project: bringing next generation TB care to underserved communities Targeted next-generation sequencing (tNGS) has the potential to revolutionise tuberculosis (TB) drug-susceptibility testing (DST) as it can provide fast, accurate, safe and comprehensive results to inform clinical decision-making for current and upcoming drug-resistant TB  treatment regimens. The Unitaid-funded Seq&Treat project is designed to generate evidence and boost in-country capacity to support  global policy and adoption of end-to-end tNGS solutions for affordable, scalable and rapid TB DST. We report results from analytical validation  of three tNGS end-to-end solutions for detecting resistance to rifampicin (RIF), isoniazid (INH), ethionamide (ETH), fluoroquinolones (FQs),  second-line injectables (amikacin (AMK), kanamycin (KAN), and capreomycin (CAP), and pyrazinamide (PZA), among others.

Anita Suresh

19:00 - 19:10: Improving interpretation of pncA gene mutations for sequencing-based drug-susceptibility testing of pyrazinamid Pyrazinamide (PZA) is a key first line anti-tuberculosis (TB) drug, which is also recommended in regimens for treating isoniazid-resistant TB and for the completion of multidrug/rifampicin-resistant TB regimens. Because of the lack of appropriate infrastructure and technical difficulties,  phenotypic drug-susceptibility testing (pDST) for PZA is not carried out in many high-incidence countries and PZA is, therefore, used  empirically. The World Health Organization has concluded that sequencing of pncA may be the most reliable method to rule-in PZA resistance.  An increasing number of low-incidence countries are introducing routine next-generation sequencing from the first positive culture for all TB  cases. In this scenario, the question becomes how to interpret the pncA sequence data and whether pDST is still needed. This study  introduces a strategy to guide the initial treatment decision and a set of rules regarding confirmatory testing and the resolution of discordant  results.

Paolo Miotto

19:10 - 19:20: Advancing the TB prevention agenda Diagnosis of tuberculosis infection (TBI) remains challenging. To estimate the public health impact and cost-effectiveness  of screening for, and treating incipient TB (ITB), a deterministic, dynamictransmission model was developed by the New Diagnostics Working Group, assuming an ITB test which meets the World Health Organization target product profile. It predicted that, to be cost-effective, the cost of an ITB test will differ widely between countries,  depending on the costing approach and control strategy. Additionally, a systematic review was performed to synthesise current evidence on the  diagnostic value of novel in vivo specific skin tests for TBI compared to currently available in vitro IGRA tests and the PPD-TST. Test  performance of novel skin tests did not differ significantly to that reported for IGRA. Finally, a framework for evaluation of new  immunodiagnostic tests for TBI was developed to facilitate their standardised evaluation. The framework describes the principles to be  considered when evaluating new tests for TBI.

Alberto Matteelli

19:20 - 19:45: Q&A session


Loading...
E-posters
EP36-Molecular testing for TB infection and drug resistance
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP36-Molecular testing for TB infection and drug resistance
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP36-445-24-Effect of switching from Xpert® MTB/RIF to Xpert® MTB/RIF-Ultra on tests done and TB cases diagnosed in Uganda: a case of assay superiority?This switch was supposed to give us more tests with an increased sensitivity of 12%-17%. Our study did not find this. We hypothesis that, if the health systems approach had been taken during the switch, all the potential benefits of the new assay would have been realised.
Michael Kakinda

EP36-446-24-Factors associated with drug-resistant TB among prisoners in Sāo Paulo State, BrazilThis study investigated the determinants of drug-resistant tuberculosis (DR-TB) among prisoners in the state of São Paulo, Brazil. It involved a retrospective cohort of DR-TB cases among prisoners. Sputum smear and culture, chest X-ray, AIDS, alcoholism and background treatment history for TB, were determinants associated with resistance to anti-TB drugs among prisoners.
Ricardo Arcêncio

EP36-447-24-Did expansion of GeneXpert machines find missing TB patients? Experience from NigeriaFrom commencement of GeneXpert implementation in 2011 to 2019, 407 GeneXpert machines (less than 45% geographical coverage across 774 local government areas) were installed in Nigeria. Starting from 2017, the TB programme shifted emphasis to GeneXpert service optimisation (47% utilisation rate) and halted installation of more machines.

Sani Useni

EP36-448-24-Xpert MTB/RIF Ultra improved the diagnosis of tuberculous meningitis in HIV-negative patients: a prospective studyThe role of Xpert MTB/RIF Ultra (Xpert Ultra) in diagnosing tuberculous meningitis(TBM) is uncertain. Implementation of Xpert Ultra in different epidemiological and geographical settings with different patient populations, might gain different benefits. We evaluated the performance of Xpert Ultra for TBM diagnosis in HIV-negative patients in China.
Mailing Huang

EP36-449-24-Hypothetical yield of serial TB screening using Xpert MTB/RIF among people living with HIV in Kampala, UgandaRoutine intensified case finding (ICF) for tuberculosis is recommended for people with HIV in TB-endemic areas, but its yield is unclear. We compared the estimated yield of two strategies - 1. baseline ICF with culture and Xpert, plus three-month ICF with Xpert only, and 2. baseline and three-month ICF with Xpert only.
Lelia Chaisson

EP36-450-24-Prevalence of gene mutations profiles by GenoType MTBDRplus in isoniazid Mycobacterium tuberculosis-resistant strains, Tunisia 2015-2019Mutations in katG and inhA promotor are involved respectively in 93.2% and 21.4% of isoniazid resistant M. tuberculosis strains. 
The aim of this study is to determine the genetic profiles of isoniazid-resistant M. tuberculosis strains in Tunisia during 2015-2019, using the molecular assay, GenoType MTBDRplus V2.0
Imen Bouzouita

EP36-451-24-Evaluation of BD MAX multidrug-resistant TB assay for detection of Mycobacterium tuberculosis complex and mutations associated with rifampicin and isoniazid resistanceEmergence of multidrug resistance in Mycobacterium tuberculosis complex (MTBC) and the length of time to diagnosis, are challenges to global tuberculosis control. New technologies, such as BD MAX MDR-TB, offer faster time to diagnosis, allowing effective treatment without a delay. We assessed suitability of the assay for use in the clinical setting.
Seb Cotton

EP36-452-24-Culture positivity rates among rifampicin-resistant indeterminate patients tested using Xpert® MTB/RIF-Ultra in high TB-HIV care settings: Uganda case studyThe World Health Organization recommends additional testing using culture and drug susceptibility testing (DST) methods for all patients initially tested with the Xpert® MTB/RIF-Ultra technique, and whose rifampicin resistance pattern is indeterminate. We determined the culture positivity rates among 75 rifampicin-resistant indeterminate patients in high TB-HIV care settings.
Didas Tugumisirize

EP36-453-24-A novel standardised artificial sputum for external quality control of the whole TB diagnostic workflowCurrently there is no validated test matrix for externally monitoring the quality of sputum-based TB diagnostics (EQA) including smear-microscopy, culture and molecular testing. We have developed a novel mucin-based artificial sputum (MUCAS) suitable for EQA panels assessing the performance of Ziehl-Neelsen microscopy, mycobacterial culture and molecular diagnostics.
Markus Beutler

EP36-454-24-The sensitivity and specificity of Xpert MTB/RIF Ultra in an active TB case finding setting and understanding the 'trace call' resultThe GeneXpert Ultra is a recent development in tackling the limitations of the MTB/Rif assay for diagnosis of paucibacillary tuberculosis. Interpretation of the 'trace call' result is a challenge, especially when used in an active case finding setting. What is new about the Xpert Ultra and the 'trace call' result?
Lophina Chilukutu

Loading...
Channel 6
OA-35-New and existing TB drug resistance
event_note
Loading...
query_builder 11:00 - 12:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-35-New and existing TB drug resistance
*Please scroll down for more information*


11:00 - 11:05: Introduction


11:05 - 11:13: OA-35-713-24-Delayed killing of M. tuberculosis in molecular bacterial load assay during early treatment in relapse patients Reliable markers for monitoring tuberculosis (TB) treatment response could accelerate clinical trials and enable personalised treatment.  We evaluated the molecular bacterial load assay (MBLA) that enumerates M. tuberculosis, measuring rRNA as a marker to determine TB-treatment responses. MBLA shows a significant difference between patients with a good long-term outcome, and those with a poor one, early on in treatment.

Nyanda Ntinginya

11:13 - 11:20: OA-35-714-24-Bedaquiline resistance in Mycobacterium tuberculosis predates its clinical use Most clinical bedaquiline resistance is conferred by mutations in the Rv0678 gene, which encodes a negative repressor of the MmpL5 efflux pump. Leveraging global datasets of >1500 lineage 2 and >2000 lineage 4 whole genome sequences, we show that the emergence of Rv0678 variants predates the clinical use of bedaquiline/clofazimine.

Camus Nimmo

11:20 - 11:28: OA-35-715-24-Primary bedaquiline resistance among drug-resistant TB cases in Taiwan Since the emergence of bedaquiline (BDQ) resistance is alarming. It is important to understand the extent of BDQ resistance in drug-resistant tuberculosis (DR-TB) patients and to design a rapid molecular diagnostic algorithm for better management of DR-TB. We identified six novel mutations. 

Sheng-Han Wu

11:28 - 11:36: OA-35-716-24-Mutation in Mycobacterium tuberculosis confer resistance to delamanid in drug-naïve patients Delamanid resistance is associated with mutations in genes of the F420 signalling pathway in Mycobacterium tuberculosis. We searched for such mutations in whole genome sequences of 129 clinical strains collected in countries with high tuberculosis (TB) burdens and their association with in vitro delamanid resistance.

Martina L. Reichmuth

11:36 - 11:44: OA-35-717-24-Heteroresistance as a predictor of treatment outcome among patients with drug-resistant TB in the Philippines We identified heteroresistance as a novel risk factor for unfavourable treatment outcome among patients with multidrug-resistant TB. This suggests that poor outcomes are, in part, due to inadequate treatment of drug-resistant subpopulations below the threshold of detection for phenotypic testing and/or treatment of drug-susceptible populations with second line drugs.

Rebecca Crowder

11:44 - 11:52: OA-35-718-24-­­Genomic context of drug resistance among Mycobacterium tuberculosis in Romania As part of a larger investigation into drug-resistant tuberculosis in the region, we sequenced M. tuberculosis clinical isolate genomes from 200 patients in Romania and performed taxonomic, comparative and predictive bioinformatics analysis. Genomes from Romania samples were compared to genomes from samples previously collected in Moldova, a neighboring, non-EU state.

Brendan Jeffrey

11:52 - 12:00: OA-35-719-24-Minimum inhibitory concentrations variability of Mycobacterium tuberculosis Peruvian strains using the UKMYC6 CRyPTIC plate The Sensititre method uses an UKMYC6 plate, designed by the CRyPTIC consortium, for minimum inhibitory concentration (MIC)-determination of several anti-tuberculosis (TB) drugs. This study evaluated the variability of anti-TB drugs MICs in Peruvian strains.

Zully M Puyén

12:00 - 12:08: OA-35-720-24-Pyrazinamide resistance among rifampicin-resistant TB patients in Yangon, Myanmar: prevalence, clinical characteristics and treatment outcomes Yangon region is reported as the highest multidrug-resistant tuberculosis (MDR-TB) burden area in Myanmar. The study reported the prevalence, clinical characteristics and treatment outcomes in relation to Pyrazinamide (PZA) resistance among rifampicin-resistant TB patients attending TB centres in Yangon in 2019-2020.

Win Ei Phyu

12:08 - 12:19: Q&A


Loading...
Channel 6
OA-38-Diagnostic assays quality and accuracy
event_note
Loading...
query_builder 12:30 - 13:50 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-38-Diagnostic assays quality and accuracy
*Please scroll down for more information*


12:30 - 12:35: Introduction


12:35 - 12:43: OA-38-735-24-Diagnostic accuracy of the Molbio Truenat TB and RIF-resistance assays in the intended setting of use We evaluated the point-of-care Molbio Truenat molecular diagnostic assays for detection of MTB and RIF resistance in a prospective, multicentre clinical trial in four countries.  We present data on assay performance in microscopy centres/primary health clinics and in reference laboratories, against culture and compared to Xpert MTB/RIF and Ultra.

Adam Penn-Nicholson

12:43 - 12:51: OA-38-736-24-SILVAMP-LAM for the diagnosis of childhood pulmonary TB in Uganda A non-sputum diagnostic for pulmonary tuberculosis (TB) in children is critically needed. Among children with presumptive pulmonary TB in Kampala, Uganda, we evaluated the diagnostic accuracy of the new urine FUJIFILM SILVAMP TB LAM (SILVAMP-LAM) assay in comparison to urine Alere Determine TB LAM Ag (LF-LAM) and sputum smear microscopy.

Devan Jaganath

12:51 - 12:59: OA-38-737-24-Diagnostic accuracy of the Xpert MTB/XDR assay for isoniazid and second line drug resistance detection A preliminary data analysis was conducted from a large-scale, multicentre clinical study of the novel Xpert MTB/XDR assay. It aimed to evaluate diagnostic performance of isoniazid, fluoroquinolone and second line injectable resistance detection against a composite reference standard of phenotypic drug-susceptibility testing and whole genome sequencing.

Adam Penn-Nicholson

12:59 - 13:07: OA-38-738-24-The diagnostic accuracy of Xpert MTB/RIF Ultra for childhood pulmonary TB in Uganda There is limited data on the performance of Xpert MTB/RIF Ultra in children. We prospectively examined the diagnostic accuracy of Xpert Ultra among children with pulmonary tuberculosis (TB) in Kampala, Uganda. We described accuracy overall - and within - subgroups, yield in children with unconfirmed TB and the frequency of trace results.

Peter Wambi

13:07 - 13:15: OA-38-739-24-External quality assurance of the Xpert MTB/RIF Ultra Assay using Mycobacterium tuberculosis isolates inactivated in PrimeStore® Molecular Transport Medium: a safe, simple and local solution Robust external quality assurance (EQA) is essential to ensure accurate results using Xpert Ultra. PrimeStore® Molecular Transport Medium (MTM) inactivates pathogens and stabilises nucleic acids for molecular testing without cold-chain requirements. We tested the idea that Mycobacterium tuberculosis isolates in PrimeStore® MTM could provide a safe, simple and locally-produced method for Xpert Ultra EQA.

Barry Kosloff

13:15 - 13:23: OA-38-740-24-Combination of Xpert MTB/RIF and Determine TB LAM assay improves the diagnosis of extrapulmonary TB in Ethiopia Xpert MTB/RIF and Determine LAM TB assays were complementary for the diagnosis of extrapulmonary tuberculosis and sensitivity of the combination of Xpert MTB/RIF and LAM assays was superior to that of either test alone.

Mulualem Tadesse

13:23 - 13:31: OA-38-741-24-Comparative analytical evaluation of four centralised platforms for the detection of M. tuberculosis complex and detection of resistance to rifampicin and isoniazid Comparative analytical assessment for four fully automated assays for detection of tuberculosis (TB) and multi-drug resistant TB (MDR-TB) - Abbott RealTime MTB and MTB RIF/INH, Hain Lifescience FluoroType® MTBDR BD MAX™ MDR-TB and Roche cobas® MTB and MTB-RIF/INH. Tested against Xpert MTB/RIF and GenoType MTBDRplus as World Health Organization-endorsed comparator tests.

Margaretha de Vos

13:31 - 13:50: Q&A


Loading...
Processing. Please wait.
Loading...